MedTrace Logo

Myo-inositol Versus Metformin in Patients With Polycystic Ovarian Syndrome to Treat Obesity

NCT07387679 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-04

No results posted yet for this study

Summary

There are considerable gaps in the comparative effectiveness and tolerability of myo-inositol and metformin for treating obesity in patients with polycystic ovarian syndrome (PCOS). The current study aimed to give insights comparing myo-inositol versus metformin for treating obesity in patients with PCOS.

Conditions

  • Polycystic Ovarian Syndrome

Interventions

DRUG

Myo-inositol

Women were given tablet myo-inositol 1 gm twice a day for 3 months.

DRUG

Metformin

Women received metformin 250 mg three times daily for 3 months.

Sponsors & Collaborators

  • Muhammad Aamir Latif

    lead OTHER

Principal Investigators

  • Ayesha Gul · Bahawal Victoria Hospital/Quid-e-Azam Medical College, Bahawalpur

  • Shehnaz Anwar, FCPS · Bahawal Victoria Hospital/Quid-e-Azam Medical College, Bahawalpur

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-29
Primary Completion
2025-05-28
Completion
2025-05-28

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07387679 on ClinicalTrials.gov